logo
Navigating earnings risk in megacap tech, and a buying opportunity in this industrial name

Navigating earnings risk in megacap tech, and a buying opportunity in this industrial name

CNBC21-07-2025
(This is a wrap-up of the key money moving discussions on CNBC's "Worldwide Exchange" exclusive for PRO subscribers. Worldwide Exchange airs at 5 a.m. ET each day.) Investors are looking for opportunities in a midcap industrial name and the financial sector. They are also looking for a way to navigate megacap tech earnings. Worldwide Exchange Pick: IEX Drew Pettit of Citi likes Idex as a way to play the spending bill President Donald Trump recently signed into law. "Idex is a small and midcap industrial company, pump valve and metering name that plays to a lot of secular themes like water, oil and gas, agriculture all supported by the 'One Big Beautiful Bill,'" Pettit said. Pettit said he's seeing broader opportunities in small- and midcap cyclicals due to a valuation discount. Idex shares are down year to date. The company reports earnings on July 30. Worldwide Exchange Pick: Financials Mark Smith of Wells Fargo sees opportunity in large cap financials. "Large Cap financials have some potential upside due to possible deregulation coming out of the executive branch this year," Smith said. "Financials are the place to be right now if you want to see outsized gains and remember they are tariff talk free, US financials don't get affected by any of this." The Invesco KBW Bank ETF holding the largest U.S. bank stocks and the SPDR S & P Regional Banking ETF that holds regional banking stocks are both outperforming the market since the Trump Administration's April 2 tariff announcement. Earnings risk in megacap tech With the Nasdaq Composite trading at an all time high and the Roundhill Magnificent Seven ETF within 1.5% of its record, Angelo Zino of CFRA is highlighting the risk to the megacap tech trade with Tesla and Alphabet reporting earnings this week. Last week, Netflix beat estimates for revenue and earnings, but the stock closed lower the day after reporting. "Our view is you are going to need a notable 'beat and raise' across the board here for the most part, outside of an Alphabet where the expectations, valuations are a little bit more reasonable in nature." He added: "If you can hear some of these companies talk about accelerating growth tied to AI, a guy like Zuckerberg at Meta … if he talks about accelerating growth here over the next 18-24 months I think that's where the stock could potentially go higher."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nvidia's China-bound H20 AI chips face Beijing scrutiny over ‘tracking' and security concerns
Nvidia's China-bound H20 AI chips face Beijing scrutiny over ‘tracking' and security concerns

CNBC

timea minute ago

  • CNBC

Nvidia's China-bound H20 AI chips face Beijing scrutiny over ‘tracking' and security concerns

While Nvidia has been given assurances by Washington that it will be allowed to resume exports of its made-for-China H20 general processing units, the AI chips may be met with increased scrutiny from Beijing. According to the Cyberspace Administration of China, Nvidia met with Beijing officials on Thursday regarding potential national security concerns posed by its H20 chips, which recently saw restrictions on their export lifted following an effective ban in April. Nvidia was requested "to clarify and submit relevant supporting documentation regarding security risks, including potential vulnerabilities and backdoors, associated with its H20 computing chips sold to China," according to a CNBC translation of a statement from CAC. In a post, the regulator said that Nvidia's computing chips were reported to have serious security vulnerabilities, also noting calls from U.S. lawmakers for mandatory tracking features to be placed on advanced chips exported from the country. In its statement, CAC added that American AI experts had already revealed that Nvidia's computing chips pose mature "tracking and positioning" and "remote shutdown" technologies. The statement appears to be referencing a report from Reuters in May that said Bill Foster, a Democrat lawmaker from Illinois, was planning to introduce legislation that would require advanced AI chipmakers like Nvidia to include a built-in location reporting system. Forester, who once worked as a particle physicist, and independent technical experts reportedly agreed that the technology to track chips was readily available, with much of it already built into Nvidia's chips. Forester's bill would also seek to give U.S. authorities the power to remotely shut down chips being used without proper licenses, in a measure to fight chip smuggling and export loopholes. Nvidia did not immediately respond to a request for comment from CNBC. In recent weeks, many American lawmakers have also taken issue with the reported rollback of restrictions on Nvidia's H20 chips, warning they will advance Beijing's AI capability. This week, Nvidia reportedly placed orders for 300,000 H20 chipsets with contract manufacturer TSMC as it seeks to meet Chinese demand.

Why Dr. Reddy's shares are down nearly 2% today? Explained
Why Dr. Reddy's shares are down nearly 2% today? Explained

Business Upturn

timean hour ago

  • Business Upturn

Why Dr. Reddy's shares are down nearly 2% today? Explained

By Aditya Bhagchandani Published on July 31, 2025, 09:44 IST Shares of Dr. Reddy's Laboratories Ltd dropped nearly 2% to ₹1,269.70 in early trade on Wednesday, reacting sharply to the overnight announcement by former U.S. President Donald Trump regarding the imposition of 25% tariffs on Indian exports to the United States. The move includes a yet-unspecified penalty for India's continued energy and defense dealings with Russia. The stock was among the worst-hit in the pharmaceutical space as investors digested the potential impact on generic drug exports, which constitute a major portion of India's pharmaceutical trade with the U.S. Pharma Exports at Risk? The United States is a critical market for Indian drugmakers. In fact, Dr. Reddy's derives 46% of its revenue from the U.S., making it highly sensitive to any changes in trade policy. While pharmaceuticals are currently exempt from the reciprocal tariff list (announced in April), officials from the White House confirmed to CNBC-TV18 that these exemptions may soon be lifted. The Department of Commerce's Section 232 investigation into Indian generic drug exports has now concluded, and according to Trump's latest statement, tariffs on pharma 'are coming soon.' Currently, India pays zero tariffs on generic drug exports to the U.S. If the proposed 25% tariff is applied to this sector, Indian companies may have to choose between: Passing the cost onto U.S. consumers , making Indian generics less price-competitive Reevaluating U.S. portfolios , withdrawing lower-margin or loss-making products Manufacturing in the U.S., which may offer no cost advantage for generics Broader Impact Across the Pharma Space Besides Dr. Reddy's, stocks likely to remain under pressure include: Sun Pharma (33% U.S. exposure) Aurobindo Pharma (45%) Gland Pharma (53%) Divi's Laboratories Cipla, Lupin, and Biocon Who Might Buck the Trend? Pharma firms and healthcare providers with a domestic business focus or minimal U.S. exposure may remain resilient: Ajanta Pharma, Eris Lifesciences, Torrent Pharma Apollo Hospitals, Fortis Healthcare, Aster DM Diagnostics players like Dr. Lal Pathlabs, Metropolis Final Word Though Indian pharma exports are not yet officially included in the tariff list, Trump's statements have created uncertainty for the sector. Until there is clarity from the U.S. Trade Representative or India's Commerce Ministry, investor sentiment around high U.S.-exposed pharma names may remain volatile. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

European markets head for broadly higher open as earnings deluge continues
European markets head for broadly higher open as earnings deluge continues

CNBC

time2 hours ago

  • CNBC

European markets head for broadly higher open as earnings deluge continues

The Millennium Bridge in London, on July 4, 2025. Jonathan Brady - Pa Images | Pa Images | Getty Images Good morning from London, and welcome to CNBC's live blog covering all the action and business news in European financial markets on Thursday. Futures data from IG suggest a broadly positive open for European indexes, with London's FTSE 100 seen opening 0.1% higher, France's CAC 40 unchanged, Germany's DAX up 0.2%, and Italy's FTSE MIB 0.3% higher. European markets closed in mixed territory Wednesday, with sectors diverging as second-quarter earnings season ramped up. There will be more earnings today, with Unilever , Shell , Anheuser-Busch Inbev, London Stock Exchange Group , BMW , Anglo American , SocGen , Renault , AF-KLM , Euronext, Sanofi, Credit Agricole and ArcelorMittal among the heavyweight regional companies that are due to report. On the data front, French, German and Italian inflation data is due, as are the latest German and EU unemployment figures. — Holly Ellyatt

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store